GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Misonix Inc (NAS:MSON) » Definitions » Intrinsic Value: Projected FCF

Misonix (Misonix) Intrinsic Value: Projected FCF : $1.98 (As of May. 12, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Misonix Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-12), Misonix's Intrinsic Value: Projected FCF is $1.98. The stock price of Misonix is $26.54. Therefore, Misonix's Price-to-Intrinsic-Value-Projected-FCF of today is 13.4.

The historical rank and industry rank for Misonix's Intrinsic Value: Projected FCF or its related term are showing as below:

MSON' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.9   Med: 2.94   Max: 66.89
Current: 13.4

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Misonix was 66.89. The lowest was 0.90. And the median was 2.94.

MSON's Price-to-Projected-FCF is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.8 vs MSON: 13.40

Misonix Intrinsic Value: Projected FCF Historical Data

The historical data trend for Misonix's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Misonix Intrinsic Value: Projected FCF Chart

Misonix Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.69 1.65 0.38 3.42 1.98

Misonix Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.42 2.70 2.61 2.30 1.98

Competitive Comparison of Misonix's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Misonix's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Misonix's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Misonix's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Misonix's Price-to-Projected-FCF falls into.



Misonix Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Misonix's Free Cash Flow(6 year avg) = $-7.11.

Misonix's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Jun21)*0.8)/Shares Outstanding (Diluted Average)
=(10.407385931648*-7.10592+135.2*0.8)/17.247
=1.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Misonix  (NAS:MSON) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Misonix's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=26.54/1.9832984380231
=13.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Misonix Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Misonix's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Misonix (Misonix) Business Description

Traded in Other Exchanges
N/A
Address
1938 New Highway, Farmingdale, NY, USA, 11735
Misonix Inc is a medical devices company. It designs, manufactures, markets, and sells invasive surgical ultrasonic medical devices. The company's products enhance clinical outcomes and provide value to the overall healthcare system. It has developed products such as BoneScalpel, NeXus, Sequel, SonaStar, SonicOne, Theragenesis, TheraSkin, and Therion. These products are used for precise bone sculpting, removal of soft and hard tumors, tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care, and maxillo-facial surgery. The company generates revenue from various regions that include the United States, the United Kingdom, the European Economic Area, Asia and the Asia Pacific, and South America.
Executives
Paul A Laviolette director ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Sharon W Klugewicz officer: Chief Operating Officer 3661 HORSEBLOCK ROAD, MEDFORD NY 11763
Thomas M Patton director C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
Joseph P Dwyer officer: Chief Financial Officer 3 CORDWOOD COURT, E. NORTHPORT NY 11731
Gwendolyn A Watanabe director C/O SARATOGA VENTURES, 210 ALMENDRA AVENUE, LOS GATOS CA 95030
Linwood A. Staub officer: Sr. VP Wound 8023 VANTAGE DRIVE SAN ANTONIO TX 78230
Stavros G. Vizirgianakis director, officer: CEO 1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016
Robert S Ludecker officer: SVP Sales - Surgical 4 WILDBRIAR COURT MOUNT SINAI NY 11766
Allan Richard Staley officer: President C/O SOLSYS MEDICAL, LLC 600 THIMBLE SHOALS BLVD., SUITE 200 NEWPORT NEWS VA 23606
Michael Koby director C/O 1315 CAPITAL 2929 WALNUT STREET, SUITE 1240 PHILADELPHIA PA 19104
1315 Capital Management, Llc 10 percent owner 2929 WALNUT STREET SUITE 1240 PHILADELPHIA PA 19104
Sv Life Sciences Fund Vi (gp), L.p. 10 percent owner ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Svlsf Vi, Llc 10 percent owner ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Sv Life Sciences Fund Vi Strategic Partners, L.p. 10 percent owner C/O SV LIFE SCIENCES ADVISERS, LLC, ONE BOSTON PLACE, SUITE 3900, BOSTON MA 02108
1315 Capital, L.p. 10 percent owner 3020 MARKET STREET, SUITE 104 PHILADELPHIA PA 19104

Misonix (Misonix) Headlines

From GuruFocus